热门资讯> 正文
Cellectar Biosciences非GAAP每股收益为-1.33美元
2026-05-14 19:18
- Cellectar Biosciences press release (CLRB): Q1 Non-GAAP EPS of -$1.33.
- As of March 31, 2026, the company had cash and cash equivalents of $8.3 million, compared to $13.2 million as of December 31, 2025, which does not reflect net proceeds of approximately $31 million from the May 2026 offering
More on Cellectar Biosciences
- Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Cellectar Biosciences
- Historical earnings data for Cellectar Biosciences
- Financial information for Cellectar Biosciences
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
